The Federal Circuit handed down an opinion last week that invalidated several asserted claims and found infringement under 35 U.S.C. § 271(e)(2) of the claims, while refusing to modify its judgment on infringement after Defendant Norwich submitted a revised ANDA containing a Section viii “carveout” in Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc….
By: McDonnell Boehnen Hulbert & Berghoff LLP
By: McDonnell Boehnen Hulbert & Berghoff LLP
